Cargando…

Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study

BACKGROUND: We designed this randomised, open-label, parallel group, multi-centre study to investigate the efficacy and safety of glycopyrronium/formoterol, a long-acting muscarinic antagonist/long-acting β2-agonist fixed dose combination, delivered through a dry powder inhaler (DPI) in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvi, Sundeep, Kumar, Anand, Agrawal, Sumit, Leuva, Amritlal, Shukla, Vineet Kumar, Deshpande, Shrikant Vishnu, Balamurugan, Santhalingam, Singh, Ajit, Tikkiwal, Sharad, Gupta, Sandeep K., Singh, Bhanu Pratap, Lopez, Meena, Sawant, Sandesh, Vaidya, Abhijit, Gogtay, Jaideep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623852/
https://www.ncbi.nlm.nih.gov/pubmed/36629200
http://dx.doi.org/10.4103/lungindia.lungindia_92_22
_version_ 1784822098610356224
author Salvi, Sundeep
Kumar, Anand
Agrawal, Sumit
Leuva, Amritlal
Shukla, Vineet Kumar
Deshpande, Shrikant Vishnu
Balamurugan, Santhalingam
Singh, Ajit
Tikkiwal, Sharad
Gupta, Sandeep K.
Singh, Bhanu Pratap
Lopez, Meena
Sawant, Sandesh
Vaidya, Abhijit
Gogtay, Jaideep
author_facet Salvi, Sundeep
Kumar, Anand
Agrawal, Sumit
Leuva, Amritlal
Shukla, Vineet Kumar
Deshpande, Shrikant Vishnu
Balamurugan, Santhalingam
Singh, Ajit
Tikkiwal, Sharad
Gupta, Sandeep K.
Singh, Bhanu Pratap
Lopez, Meena
Sawant, Sandesh
Vaidya, Abhijit
Gogtay, Jaideep
author_sort Salvi, Sundeep
collection PubMed
description BACKGROUND: We designed this randomised, open-label, parallel group, multi-centre study to investigate the efficacy and safety of glycopyrronium/formoterol, a long-acting muscarinic antagonist/long-acting β2-agonist fixed dose combination, delivered through a dry powder inhaler (DPI) in patients with chronic obstructive pulmonary disease (COPD). MATERIAL AND METHODS: We randomised (1:1) patients with moderate to severe COPD (N = 356) to receive glycopyrronium 25 µg/formoterol 12 µg via DPI twice daily (GF-DPI) or glycopyrronium 50 µg monotherapy via DPI once daily (G-DPI). The primary study endpoint was the mean change from the baseline in pre-dose trough-forced expiratory volume in one second (FEV(1)) at 12 weeks. RESULTS: At week 12, the mean increase from the baseline in pre-dose trough FEV(1) was higher in the GF-DPI group (120 ml) than in the G-DPI (60 ml) group. The mean difference (MD) between treatment groups was 0.06 L (95% CI: 0.00–0.12 L, P < 0.0001 for non-inferiority). At week 12, the mean pre-dose forced vital capacity (FVC), 1 hour post-dose FEV(1), and post-dose FVC increased significantly from the baseline only in the GF-DPI group (p < 0.0001). The reduction in the COPD assessment test score was greater in the GF-DPI group (p = 0.0379). The average daily number of puffs of rescue medication and the reduction in mean modified Medical Research Council scale, COPD, and Asthma Sleep Impact Scale score at week 12 were similar between groups (p > 0.05). Overall, 35 adverse events and two serious adverse events unrelated to study drugs were reported. Both groups had similar results for overall drug safety. CONCLUSION: The results demonstrate efficacy and safety of GF-DPI in Indian patients with moderate to severe COPD. Treatment with GF-DPI significantly improved the lung function and quality of life and was well tolerated.
format Online
Article
Text
id pubmed-9623852
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-96238522022-11-02 Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study Salvi, Sundeep Kumar, Anand Agrawal, Sumit Leuva, Amritlal Shukla, Vineet Kumar Deshpande, Shrikant Vishnu Balamurugan, Santhalingam Singh, Ajit Tikkiwal, Sharad Gupta, Sandeep K. Singh, Bhanu Pratap Lopez, Meena Sawant, Sandesh Vaidya, Abhijit Gogtay, Jaideep Lung India Original Article BACKGROUND: We designed this randomised, open-label, parallel group, multi-centre study to investigate the efficacy and safety of glycopyrronium/formoterol, a long-acting muscarinic antagonist/long-acting β2-agonist fixed dose combination, delivered through a dry powder inhaler (DPI) in patients with chronic obstructive pulmonary disease (COPD). MATERIAL AND METHODS: We randomised (1:1) patients with moderate to severe COPD (N = 356) to receive glycopyrronium 25 µg/formoterol 12 µg via DPI twice daily (GF-DPI) or glycopyrronium 50 µg monotherapy via DPI once daily (G-DPI). The primary study endpoint was the mean change from the baseline in pre-dose trough-forced expiratory volume in one second (FEV(1)) at 12 weeks. RESULTS: At week 12, the mean increase from the baseline in pre-dose trough FEV(1) was higher in the GF-DPI group (120 ml) than in the G-DPI (60 ml) group. The mean difference (MD) between treatment groups was 0.06 L (95% CI: 0.00–0.12 L, P < 0.0001 for non-inferiority). At week 12, the mean pre-dose forced vital capacity (FVC), 1 hour post-dose FEV(1), and post-dose FVC increased significantly from the baseline only in the GF-DPI group (p < 0.0001). The reduction in the COPD assessment test score was greater in the GF-DPI group (p = 0.0379). The average daily number of puffs of rescue medication and the reduction in mean modified Medical Research Council scale, COPD, and Asthma Sleep Impact Scale score at week 12 were similar between groups (p > 0.05). Overall, 35 adverse events and two serious adverse events unrelated to study drugs were reported. Both groups had similar results for overall drug safety. CONCLUSION: The results demonstrate efficacy and safety of GF-DPI in Indian patients with moderate to severe COPD. Treatment with GF-DPI significantly improved the lung function and quality of life and was well tolerated. Wolters Kluwer - Medknow 2022 2022-08-29 /pmc/articles/PMC9623852/ /pubmed/36629200 http://dx.doi.org/10.4103/lungindia.lungindia_92_22 Text en Copyright: © 2022 Indian Chest Society https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Salvi, Sundeep
Kumar, Anand
Agrawal, Sumit
Leuva, Amritlal
Shukla, Vineet Kumar
Deshpande, Shrikant Vishnu
Balamurugan, Santhalingam
Singh, Ajit
Tikkiwal, Sharad
Gupta, Sandeep K.
Singh, Bhanu Pratap
Lopez, Meena
Sawant, Sandesh
Vaidya, Abhijit
Gogtay, Jaideep
Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study
title Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study
title_full Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study
title_fullStr Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study
title_full_unstemmed Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study
title_short Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study
title_sort efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: results from a multi-centre, open-label, randomised study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623852/
https://www.ncbi.nlm.nih.gov/pubmed/36629200
http://dx.doi.org/10.4103/lungindia.lungindia_92_22
work_keys_str_mv AT salvisundeep efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT kumaranand efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT agrawalsumit efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT leuvaamritlal efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT shuklavineetkumar efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT deshpandeshrikantvishnu efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT balamurugansanthalingam efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT singhajit efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT tikkiwalsharad efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT guptasandeepk efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT singhbhanupratap efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT lopezmeena efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT sawantsandesh efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT vaidyaabhijit efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy
AT gogtayjaideep efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy